Summit Therapeutics INC 8-K filings

Summit Therapeutics announced positive results from Phase III trials for ivonescimab, including a statistically significant improvement over pembrolizumab, and secured $200 million in funding, extending their cash runway into Q4 2025.

Summit Therapeutics has appointed Jeff Huber to its board of directors and subleased office space to two affiliates of Robert W. Duggan.

Summit Therapeutics reports the resignation of a board member and the successful outcomes of its 2024 Annual Meeting of Stockholders.

Summit Therapeutics has announced a $200 million private placement and an expansion of its ivonescimab license territories to include Latin America, the Middle East, and Africa.

Summit Therapeutics announced positive results from the HARMONi-A trial, leading to marketing authorization for ivonescimab in China and publication in the Journal of the American Medical Association.

Summit Therapeutics announced that its drug, ivonescimab, demonstrated a statistically significant improvement in progression-free survival compared to pembrolizumab in a Phase III trial for non-small cell lung cancer.

The National Medical Products Administration (NMPA) in China has approved ivonescimab in combination with chemotherapy for specific lung cancer patients, marking the first regulatory approval for the drug.

Summit Therapeutics has entered into a distribution agreement with J.P. Morgan Securities to potentially sell up to $90 million of its common stock through an at-the-market offering.

Summit Therapeutics announced first quarter 2024 financial results and provided an update on the clinical progress of ivonescimab, including promising intracranial anti-tumor activity data.

Summit Therapeutics has appointed Dr. Mostafa Ronaghi, a renowned executive and genomicist, to its Board of Directors, effective immediately.

Summit Therapeutics has appointed its COO, Manmeet Soni, as CFO following the resignation of Ankur Dhingra, and hired Bhaskar Anand as Chief Accounting Officer.

Summit Therapeutics presented updated data at the European Lung Cancer Congress showing promising results for ivonescimab, a bispecific antibody, in treating non-small cell lung cancer, including brain metastases.

Summit Therapeutics presented at the Barclays Global Healthcare Conference, focusing on the development of their lead drug candidate, ivonescimab, a novel bispecific antibody currently in Phase III clinical trials.

Summit Therapeutics will present at the Barclays 26th Annual Global Healthcare Conference, focusing on the development of their bispecific antibody, ivonescimab.

Summit Therapeutics announced positive clinical data for its lead drug candidate, ivonescimab, and extended its cash runway into the first quarter of 2025.

Summit Therapeutics presented at the Oppenheimer Healthcare Life Sciences Conference, focusing on the development of their lead drug candidate, ivonescimab, a novel bispecific antibody.

Summit Therapeutics will present at the Oppenheimer's 34th Annual Healthcare Life Sciences Conference, focusing on the development of their bispecific antibody, ivonescimab.